Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of dihydrocurcumin in the preparation of medicine for treating non-alcoholic fatty liver diseases

A dihydrocurcumin, non-alcoholic technology, applied in the field of new application in the preparation of drugs for the treatment of non-alcoholic fatty liver, can solve the problems that dihydrocurcumin has little pharmacological activity research, and has not yet discovered the treatment of NAFLD.

Inactive Publication Date: 2018-11-27
HUBEI UNIV
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are few studies on the pharmacological activity of dihydrocurcumin, and there is no report on its treatment of NAFLD

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of dihydrocurcumin in the preparation of medicine for treating non-alcoholic fatty liver diseases
  • Application of dihydrocurcumin in the preparation of medicine for treating non-alcoholic fatty liver diseases
  • Application of dihydrocurcumin in the preparation of medicine for treating non-alcoholic fatty liver diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0031] Firstly, the dosage was determined by MTT experiment. The results of MTT experiment showed that 0-20μM DHC had no obvious effect on the proliferation of HepG2 cells, but it had a significant inhibitory effect at 50-100μM. 0-50μM DHC has no obvious effect on the viability of L02 cells, and it has a significant inhibitory effect at 100μM. In the following experiments, the administration concentration of DHC was selected as: when acting on HepG2 cells, the administration concentration: 5 μM, 10 μM, 20 μM; when acting on L02 cells, the administration concentration: 5 μM, 20 μM, 50 μM. The action time is 24h.

[0032] 1. Effect of DHC on TG in HepG2 and L02 cells

[0033] HepG2 and L02 cells were treated with different concentrations of DHC for 24 hours, and the relative content of TG in the cells was detected by the TG kit. The results are as follows: figure 1 shown.

[0034] The results showed that the model group treated with oleic acid significantly increased the con...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of dihydrocurcumin in the preparation of a medicine for treating non-alcoholic fatty liver diseases. In vitro cell experiments showed that (1) the dihydrocurcumin reduces the TG content in hepatocytes and improves hepatic lipid metabolism by decreasing expression of SREBP-1C, PNPLA3 mRNA and protein in the hepatocytes and increasing expression of PPARa mRNA and protein, (2) the dihydrocurcumin increases expression of PI3K / AKT in the hepatocytes and improves the ability of the hepatocytes to absorb glucose so as to enhance the insulin sensitivity, (3) thedihydrocurcumin reduces the ROS content so as to improve oxidative stress by increasing expression of Nrf2 protein in the hepatocytes and decreasing expression of CYP4A, and (4) the dihydrocurcumin alleviates inflammation by reducing the NO content in the hepatocytes. Therefore, the dihydrocurcumin is an excellent candidate medicine for the treatment of the non-alcoholic fatty liver diseases.

Description

technical field [0001] The invention belongs to the field of pharmacy, and relates to a new application of dihydrocurcumin, in particular to a new application in preparing medicine for treating non-alcoholic fatty liver. Background technique [0002] Non-alcoholic fatty liver disease (NAFLD) refers to a syndrome caused by non-alcoholic and other unclear liver damage factors. The main clinical feature is that the liver cells are diffuse, accompanied by large vesicular fat Lesions, including simple fatty liver, non-alcoholic steatohepatitis and liver cirrhosis in three stages. NAFLD is often associated with obesity and hyperglycemia, along with high triglycerides, high blood pressure and high cholesterol. [0003] Since the pathogenesis of NAFLD is complex and the cause is still unclear, there is currently no definite specific drug. Controlling diet, correcting unhealthy life routines, and strengthening physical exercise to control weight are the best ways to control NAFLD. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/12A61P1/16A61P29/00
CPCA61K31/12A61P1/16A61P29/00
Inventor 陈勇喻青青刘亚云
Owner HUBEI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com